Lung Cancer | Specialty

Ensartinib Significantly Prolongs PFS Over Crizotinib in ALK+ NSCLC

August 8th 2020

Ensartinib showed a significant improvement in progression-free survival over crizotinib with a favorable safety profile in patients with ALK-positive non–small cell lung cancer.

Sintilimab/Pemetrexed Regimen Significantly Improves PFS in Advanced NSCLC

August 8th 2020

Sintilimab injection plus pemetrexed and platinum-based therapy led to a statistically significant improvement in progression-free survival compared with chemotherapy alone as a first-line treatment for patients with locally advanced or metastatic nonsquamous non–small cell lung cancer.

Dr. Chiang on the Rationale for Chemoimmunotherapy in Lung Cancer

August 7th 2020

Anne Chiang, MD, PhD, discusses the rationale for combining immunotherapy with chemotherapy in lung cancer.

FDA Approves Guardant360 CDx Liquid Biopsy for Comprehensive Genomic Profiling Across All Solid Cancers

August 7th 2020

The FDA has approved Guardant360® CDx for comprehensive genomic profiling in patients with any solid malignant cancer.

Thoracic Leaders Examine Novel Treatment Options in Mesothelioma

August 7th 2020

In a special OncLive video program, The Board, Joshua M. Bauml, MD, led a discussion regarding key abstracts that were presented during the 2020 ASCO Virtual Scientific Program in mesothelioma.

Multidisciplinary Collaboration Needed to Provide Cohesive Care in Advanced NSCLC

August 7th 2020

David R. Spigel, MD, discusses the Fostering Excellence in Care and Outcomes in Patients with Stage III and IV NSCLC initiative, analyzes the survey data, and next steps for the research.

Dr. Kelly on Window-of-Opportunity Monotherapy Trials in Lung Cancer

August 7th 2020

Karen Kelly, MD, discusses the experimental window-of-opportunity studies with monotherapies in lung cancer.

Next-Generation TKIs Continue to Impress in ALK+ and ROS1+ NSCLC

August 6th 2020

Vamsidhar Velcheti, MD, discusses the current and emerging treatment options for patients with ALK- and ROS1-positive non–small cell lung cancer.

Experts Analyze Striking ASCO 2020 Data in Small Cell Lung Cancer

August 5th 2020

In a special OncLive video program, The Board, Joshua M. Bauml, MD, led a discussion regarding key abstracts that were presented during the 2020 ASCO Virtual Scientific Program in extensive-stage SCLC and limited-stage SCLC.

Lorlatinib Significantly Improves PFS in Frontline ALK+ NSCLC

August 5th 2020

Lorlatinib significantly improved progression-free survival in treatment-naive patients with advanced ALK-positive non–small cell lung cancer versus crizotinib, meeting the primary end point of the phase 3 CROWN trial.

Expert Outlines Opportunities With Osimertinib in EGFR-Mutant NSCLC

August 5th 2020

Elaine Shum, MD, sheds light on osimertinib as the standard of care in the frontline treatment of patients with EGFR-mutant non–small cell lung cancer, which may be on its way to becoming a key player in the adjuvant setting and a promising option to include with novel combinations.

Dr. Shum on Patient Consultation of Osimertinib in NSCLC

August 4th 2020

Elaine Shum, MD, discusses consulting patients with non-small cell lung cancer on the use of osimertinib.

Entrectinib Approved in Europe for NTRK+ Tumors and ROS1+ NSCLC

August 3rd 2020

The European Commission has approved entrectinib for the treatment of adult and pediatric patients ≥12 years of age with solid tumors that harbor an NTRK fusion, as well as for the treatment of adult patients with ROS1-positive, advanced non—small cell lung cancer not previously treated with ROS1 inhibitors.

KRAS G12C Inhibition in Advanced NSCLC: MRTX849

August 3rd 2020

KRAS G12C Inhibition in Advanced NSCLC: AMG 510

August 3rd 2020

Development of KRAS G12C-Targeted Therapy in NSCLC

August 3rd 2020

Systemic Therapy for KRAS+ Advanced NSCLC

August 3rd 2020

Counseling Patients With NSCLC When KRAS is Detected

August 3rd 2020

Testing for KRAS Mutations in NSCLC

August 3rd 2020

KRAS Mutations in Solid Tumors

August 3rd 2020